XenoPort to Present at the Jefferies 2015 Global Healthcare Conference
May 18 2015 - 10:00AM
Business Wire
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will
provide access via the World Wide Web to its presentation at the
Jefferies 2015 Global Healthcare Conference. The live presentation
will occur at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) on
Thursday, June 4, 2015. A replay of the presentation will also be
available.
To access the live presentation via the Web, please go to
www.XenoPort.com. Please connect to the website at least 15 minutes
prior to the live presentation to ensure adequate time for any
software downloads that may be necessary to listen to the
Webcast.
A replay of the Webcast can be accessed for a minimum of one
month and will be available approximately 24 hours after the live
presentation.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on
developing and commercializing a portfolio of internally discovered
product candidates for the potential treatment of neurological
disorders. XenoPort is currently commercializing HORIZANT®
(gabapentin enacarbil) Extended-Release Tablets in the United
States and developing its novel fumaric acid ester product
candidate, XP23829, as a potential treatment for patients with
moderate-to-severe chronic plaque-type psoriasis and potentially
for relapsing forms of multiple sclerosis. REGNITE® (gabapentin
enacarbil) Extended-Release Tablets is being marketed in Japan by
Astellas Pharma Inc. XenoPort has entered into a clinical trial
agreement with the National Institute on Alcohol Abuse and
Alcoholism (NIAAA) under which the NIAAA plans to conduct a
clinical trial evaluating gabapentin enacarbil as a potential
treatment for alcohol use disorder, and XenoPort has granted
exclusive world-wide rights for the development and
commercialization of its clinical-stage oral product candidate,
arbaclofen placarbil, to Indivior PLC for all indications.
XenoPort's pipeline of product candidates also includes a potential
treatment for patients with idiopathic Parkinson's disease.
To learn more about XenoPort, please visit the website at
www.XenoPort.com.
XNPT2G
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150518005471/en/
XenoPort, Inc.Jackie Cossmon, 408-616-7220ir@XenoPort.com
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Apr 2023 to Apr 2024